| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
| ln Vitro |
Scaffolds are rescued by pargyline HCl (0.5-2 mM; 24-120 hr; LNCaP-LN3 cells) in a mold- and time-assisted manner [2]. In a quantitatively dependent way, pargyline HCl (0.5-2 mM; 24-48 h; LNCaP) and pargyline HCl (0.5 mM; 24 h; LNCaP-LN3 cells) therapy decreases S phase and enhances G1 phase in cells [2]. LNCaP-LN3 cells treated with 0.5 mM pargyline hydrochloride for 24 hours results in an increase in sterile cells [2]. The administration of 2 mM for 48 hours to LNCaP-LN3 cells results in an upregulation of intracellular caspase-3 and cytochrome c. decrease, although it has no effect on BCL-2 expression alterations [2].
|
|---|---|
| ln Vivo |
In unanesthetized spontaneous gradients (SHR), pargyline hydrochloride (10 mg/kg; intravenous) treatment results in a moderate (roughly 20 mmc) but sustained (48 h) contraction reduction, but not in normotensive The middle will not [3]. Arterial pressure is lowered by injecting 200 μg of low-dose pargyline hydrochloride (icv) directly into the brain. The buildup of inhibitory alpha-receptin receptors in the brain appears to be the cause of pargyline hydrochloride's antihypertensive effect in SHR [3].
|
| Cell Assay |
Cell Proliferation Assay[2]
Cell Types: LNCaP- LN3 Cell Tested Concentrations: 0.5 mM, 1 mM, 1.5 mM or 2 mM Incubation Duration: 24 hrs (hours), 48 hrs (hours), 72 hrs (hours), 96 hrs (hours) or 120 hrs (hours) Experimental Results: Time and dose dependent Sexual intercourse inhibits the proliferation of prostate cancer cells. Cell cycle analysis [2] Cell Types: LNCaP-LN3 Cell Tested Concentrations: 0.5 mM, 2 mM Incubation Duration: 24 hrs (hours), 48 hrs (hours) Experimental Results: The proportion of cells in S phase diminished and the proportion of G1 phase increased. Apoptosis analysis[2] Cell Types: LNCaP-LN3 Cell Tested Concentrations: 0.5 mM Incubation Duration: 24 hrs (hours) Experimental Results: Increased apoptotic cells. Western Blot Analysis[2] Cell Types: LNCaP-LN3 Cell Tested Concentrations: 2 mM Incubation Duration: 48 hrs (hours) Experimental Results: Induction of increased cytochrome c and diminished caspase-3. |
| References |
|
| Additional Infomation |
Pargyline is an aromatic amine.
Pargyline is a monoamine oxidase inhibitor with antihypertensive properties. Pargyline is a monoamine oxidase (MAO) inhibitor with antidepressant activity. Pargyline selectively inhibits MAO type B, an enzyme catalyzing the oxidative deamination and inactivation of certain catecholamines, such as norepinephrine and dopamine, within the presynaptic nerve terminals. By inhibiting the metabolism of these biogenic amines in the brain, pargyline increases their concentration and binding to postsynaptic receptors. Increased receptor stimulation may cause downregulation of central receptors which may attribute to pargyline's antidepressant effect. A monoamine oxidase inhibitor with antihypertensive properties. See also: Methyclothiazide; pargyline hydrochloride (annotation moved to). Drug Indication For the treatment of moderate to severe hypertension. Mechanism of Action MAOIs act by inhibiting the activity of monoamine oxidase, thus preventing the breakdown of monoamine neurotransmitters and thereby increasing their availability. There are two isoforms of monoamine oxidase, MAO-A and MAO-B. MAO-A preferentially deaminates serotonin, melatonin, epinephrine and norepinephrine. MAO-B preferentially deaminates phenylethylamine and trace amines. Pargyline functions by inhibiting the metabolism of catecholamines and tyramine within presynaptic nerve terminals. Catecholamines cause general physiological changes that prepare the body for physical activity (fight-or-flight response). Some typical effects are increases in heart rate, blood pressure, blood glucose levels, and a general reaction of the sympathetic nervous system. |
| Molecular Formula |
C11H14CLN
|
|---|---|
| Molecular Weight |
195.69
|
| Exact Mass |
195.081
|
| CAS # |
306-07-0
|
| Related CAS # |
Pargyline;555-57-7
|
| PubChem CID |
4688
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
228.4ºC at 760 mmHg
|
| Melting Point |
160-163ºC
|
| Flash Point |
83.9ºC
|
| LogP |
2.553
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
12
|
| Complexity |
159
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
BCXCABRDBBWWGY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H13N.ClH/c1-3-9-12(2)10-11-7-5-4-6-8-11/h1,4-8H,9-10H2,2H31H
|
| Chemical Name |
N-benzyl-N-methylprop-2-yn-1-aminehydrochloride
|
| Synonyms |
Pargyline Hydrochloride N-benzyl-N-methylprop-2-yn-1-amine hydrochloride Eutonyl-ten N-Methyl-N-propargylbenzylamine hydrochloride Pargyline HCl Pargyline
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~638.77 mM)
H2O : ~100 mg/mL (~511.01 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (10.63 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (10.63 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (10.63 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 25 mg/mL (127.75 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with heating and sonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.1101 mL | 25.5506 mL | 51.1012 mL | |
| 5 mM | 1.0220 mL | 5.1101 mL | 10.2202 mL | |
| 10 mM | 0.5110 mL | 2.5551 mL | 5.1101 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
